Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

anton hagenbeek Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

ASCO Logo Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

This entry was posted in Oncology and tagged , , , , , , , , , , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>